Follicular Lymphoma
The latest news, research, and perspectives in follicular lymphoma (FL).
Advertisement
Elizabeth Brem, MD provides valuable insights for clinicians and researchers focused on advancing care in FL.
Relmacabtagene autoleucel is an anti-CD19 chimeric antigen receptor T-cell product
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
The 5-year follow-up analysis of ZUMA-5 showed continued efficacy and no new safety signals.
Data support rituximab over watchful waiting in front-line therapy for low-tumor-burden follicular lymphoma, study concludes.
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
Advertisement
Researchers at the 2024 American Society of Hematology Annual Meeting said follicular lymphoma is biologically diverse.
The efficacy of HSCT for FL and provides a benchmark for testing emerging therapies like CAR-T and bispecific antibodies.
According to Jeremey S. Abramson, MD, TRANSCEND FL showed the highest CR ever reported in high-risk follicular lymphoma.
Marginal zone lymphoma lacks extensive research on its real-world treatment patterns and economic impact.
Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.
CTX112, a next-generation allogeneic CRISPR-Cas9–engineered showing encouraging results in B-cell malignancies.
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
A large, multicenter retrospective study found favorable efficacy and toxicity with this approach.
Odronextamab achieved high ORR and CR rates in patients with relapsed or refractory third line FL
A study stresses psychological support as an essential component of comprehensive cancer care.
A phase I/II first-in-human study evaluates a new bivalent small molecule in relapsed or refractory FL and MZL.
CD19-directed CAR-T therapy led to improved survival in patients with transformed follicular lymphoma.
The positive safety profile of this bispecific antibody makes it well-suited for combination with other treatments.
The approval is based on results from the phase I ELM-1 and phase II ELM-2 trials.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.